RABBIT ANTITHYMOCYTE GLOBULIN VERSUS ALEMTUZUMAB IN ALLOGENEIC STEM CELL TRANSPLANTATION：A META-ANALYSIS
(Abstract release date: 05/19/16)
EHA Library. ZHANG C. 06/09/16; 135381; LB2270
Prof. Cheng ZHANG
Contributions
Contributions
Abstract
Abstract: LB2270
Type: Eposter Presentation
Background
Rabbit antithymocyte globulin (ATG) and alemtuzumab have been used for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation, but which is more efficient remain unclear.
Aims
This study is to analysize the role of rabbit antithymocyte globulin versus alemtuzumab in allogeneic stem cell transplantation.
Methods
we perform a meta-analysis of all studies comparing rabbit antithymocyte globulin (ATG) and alemtuzumab for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation to evaluate their benefits and drawbacks. There are 7 studies (one prospective and six retrospective)for comparing ATG vs alemtuzumab in GVHD prophylaxis with 622 patients.
Results
Our results showed that the incidence of grade II-IV acute GVHD(RR 1.51, 95% CI 0.97–2.34, P = 0.07), incidence of grade III-IV acute GVHD (RR 1.48, 95% CI 0.63–3.47, P = 0.37) had a statistically non-significant reduction in alemtuzumab group, however, alemtuzumab significantly impaired OS (HR 0.61 (95% CI 0.41–0.90, P = 0.01) compared with ATG. The incidence of overall chronic GVHD(RR 0.97, 95% CI 0.67–1.40, P = 0.87) and the incidence of relapse(RR 1.03, 95% CI 0.72–1.47, P = 0.88) were similar in the two groups.
Conclusion
We propose that using alemtuzumab for GVHD prophylaxis is beneficial for allogeneic stem cell transplantation due to the efficacy in grade III/IV acute GVHD, but OS is impaired compared with ATG group.
Session topic: E-poster
Keyword(s): Antithymocyte globulin, Stem cell transplant
Type: Eposter Presentation
Background
Rabbit antithymocyte globulin (ATG) and alemtuzumab have been used for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation, but which is more efficient remain unclear.
Aims
This study is to analysize the role of rabbit antithymocyte globulin versus alemtuzumab in allogeneic stem cell transplantation.
Methods
we perform a meta-analysis of all studies comparing rabbit antithymocyte globulin (ATG) and alemtuzumab for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation to evaluate their benefits and drawbacks. There are 7 studies (one prospective and six retrospective)for comparing ATG vs alemtuzumab in GVHD prophylaxis with 622 patients.
Results
Our results showed that the incidence of grade II-IV acute GVHD(RR 1.51, 95% CI 0.97–2.34, P = 0.07), incidence of grade III-IV acute GVHD (RR 1.48, 95% CI 0.63–3.47, P = 0.37) had a statistically non-significant reduction in alemtuzumab group, however, alemtuzumab significantly impaired OS (HR 0.61 (95% CI 0.41–0.90, P = 0.01) compared with ATG. The incidence of overall chronic GVHD(RR 0.97, 95% CI 0.67–1.40, P = 0.87) and the incidence of relapse(RR 1.03, 95% CI 0.72–1.47, P = 0.88) were similar in the two groups.
Conclusion
We propose that using alemtuzumab for GVHD prophylaxis is beneficial for allogeneic stem cell transplantation due to the efficacy in grade III/IV acute GVHD, but OS is impaired compared with ATG group.
Session topic: E-poster
Keyword(s): Antithymocyte globulin, Stem cell transplant
Abstract: LB2270
Type: Eposter Presentation
Background
Rabbit antithymocyte globulin (ATG) and alemtuzumab have been used for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation, but which is more efficient remain unclear.
Aims
This study is to analysize the role of rabbit antithymocyte globulin versus alemtuzumab in allogeneic stem cell transplantation.
Methods
we perform a meta-analysis of all studies comparing rabbit antithymocyte globulin (ATG) and alemtuzumab for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation to evaluate their benefits and drawbacks. There are 7 studies (one prospective and six retrospective)for comparing ATG vs alemtuzumab in GVHD prophylaxis with 622 patients.
Results
Our results showed that the incidence of grade II-IV acute GVHD(RR 1.51, 95% CI 0.97–2.34, P = 0.07), incidence of grade III-IV acute GVHD (RR 1.48, 95% CI 0.63–3.47, P = 0.37) had a statistically non-significant reduction in alemtuzumab group, however, alemtuzumab significantly impaired OS (HR 0.61 (95% CI 0.41–0.90, P = 0.01) compared with ATG. The incidence of overall chronic GVHD(RR 0.97, 95% CI 0.67–1.40, P = 0.87) and the incidence of relapse(RR 1.03, 95% CI 0.72–1.47, P = 0.88) were similar in the two groups.
Conclusion
We propose that using alemtuzumab for GVHD prophylaxis is beneficial for allogeneic stem cell transplantation due to the efficacy in grade III/IV acute GVHD, but OS is impaired compared with ATG group.
Session topic: E-poster
Keyword(s): Antithymocyte globulin, Stem cell transplant
Type: Eposter Presentation
Background
Rabbit antithymocyte globulin (ATG) and alemtuzumab have been used for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation, but which is more efficient remain unclear.
Aims
This study is to analysize the role of rabbit antithymocyte globulin versus alemtuzumab in allogeneic stem cell transplantation.
Methods
we perform a meta-analysis of all studies comparing rabbit antithymocyte globulin (ATG) and alemtuzumab for graft-versus-host disease(GVHD) prophylaxis in allogeneic haematopoietic stem cell transplantation to evaluate their benefits and drawbacks. There are 7 studies (one prospective and six retrospective)for comparing ATG vs alemtuzumab in GVHD prophylaxis with 622 patients.
Results
Our results showed that the incidence of grade II-IV acute GVHD(RR 1.51, 95% CI 0.97–2.34, P = 0.07), incidence of grade III-IV acute GVHD (RR 1.48, 95% CI 0.63–3.47, P = 0.37) had a statistically non-significant reduction in alemtuzumab group, however, alemtuzumab significantly impaired OS (HR 0.61 (95% CI 0.41–0.90, P = 0.01) compared with ATG. The incidence of overall chronic GVHD(RR 0.97, 95% CI 0.67–1.40, P = 0.87) and the incidence of relapse(RR 1.03, 95% CI 0.72–1.47, P = 0.88) were similar in the two groups.
Conclusion
We propose that using alemtuzumab for GVHD prophylaxis is beneficial for allogeneic stem cell transplantation due to the efficacy in grade III/IV acute GVHD, but OS is impaired compared with ATG group.
Session topic: E-poster
Keyword(s): Antithymocyte globulin, Stem cell transplant
{{ help_message }}
{{filter}}